How AI Could Change Novartis Stock Over the Next Decade

01. Historical Context

How AI enters the valuation debate for Novartis

Novartis has a more mature AI narrative than many industrial or healthcare peers. The company says it has already developed more than 100 AI use cases across R&D, operations, and commercial activity, which suggests AI is part of the operating model rather than a pilot program.

That matters because Novartis has also described an AI ambition to bring medicines to patients two years faster and reduce costs by USD 1 billion to USD 2 billion. In February 2026, the company highlighted a real-world AI platform that uses data from more than 2,500 urology practices, 200 oncology practices, and 56,000 metastatic prostate cancer patients.

Those are useful signals for a 10-year stock thesis. They suggest Novartis is trying to apply AI across research, commercial execution, and real-world evidence rather than keeping it as a lab-only concept.

AI investment case for Novartis built from company disclosures and current stock data — AI scenario framework tied only to company disclosures and the current stock setup, not to generic AI hype.

Novartis framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were USD 13.1 billion, down 5% at constant currencies, while core EPS was USD 1.99, down 15% at constant currencies.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Novartis at about 19.2x trailing 2025 earnings, 20.1x 2026 estimated earnings, and 17.3x 2027 estimated earnings. Consensus EPS on MarketScreener was USD 7.244 for 2026 and USD 8.433 for 2027, implying roughly 16.4% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2035	Structural compounding	10-year price range CHF 39.77 to CHF 126.65; 10-year CAGR 10.0%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five ways AI could materially change the thesis

The first AI channel is clinical and research efficiency. Faster molecule selection and trial design would improve capital efficiency across the pipeline.

The second channel is real-world evidence. The PRECISION platform shows Novartis is using AI and large-scale community data to influence treatment decisions and insight generation.

The third channel is operations. Novartis says it uses digital technologies across planning, procurement, manufacturing, and logistics, which matters because scale and supply reliability are real competitive assets in pharma.

The fourth channel is cost leverage. A stated ambition to cut USD 1 billion to USD 2 billion of cost is large enough to matter if execution is real.

The fifth channel is platform selection. Novartis is investing across radioligand therapy, xRNA, and other advanced modalities where data and manufacturing complexity are high enough for AI to have real value.

Current factor scorecard for Novartis

Factor	Current Assessment	Bias	Why it matters now
AI use cases	More than 100 already developed	Bullish	This is beyond pilot-stage experimentation.
Cost ambition	USD 1 billion to USD 2 billion	Bullish	Large enough to matter if executed.
Speed ambition	Bring medicines to patients two years faster	Bullish	Development speed has direct economic value.
Real-world evidence	PRECISION uses data from 2,500+ urology practices, 200 oncology practices, and 56,000 patients	Bullish	Concrete evidence of scaled AI deployment.
Direct disclosure	No explicit AI revenue line yet	Neutral	Value still has to show up indirectly through margins and pipeline output.

03. Countercase

Why the AI story can still disappoint investors

The AI bear case is that scale alone does not guarantee alpha. More than 100 use cases sounds impressive, but investors still need to see which ones change drug economics, approval speed, or cost structure enough to matter.

A second risk is that AI savings arrive more slowly than expected. The ambition to reduce costs by USD 1 billion to USD 2 billion is significant, but it is still an ambition rather than a reported realized number in the latest quarter.

A third risk is that the company remains judged primarily on patent cycles and launches. If generic erosion dominates investor attention, AI can be strategically important without helping the stock in the near term.

Current constraints on the AI thesis

Risk	Latest datapoint	Current assessment	Bias
Savings realization	Cost ambition disclosed, but not yet fully proven in reported numbers	Needs verification over time	Neutral
Stock-market translation	Q1 2026 was still dominated by generic erosion	AI not enough to override core pharma issues	Neutral
Execution complexity	AI spans R&D, manufacturing, and commercial data	Complex but promising	Neutral
Platform fit	Advanced modalities are data-heavy and AI-relevant	Supports upside	Bullish offset

04. Institutional Lens

What the better AI evidence actually supports

Novartis gives enough official evidence to treat AI as more than a slogan. The company has published a responsible-AI framework, disclosed more than 100 use cases, and described cost and speed ambitions large enough to matter economically.

The right institutional caution comes from the IMF rather than from another company. In April 2026, the IMF said disappointment over AI productivity remained a downside macro risk. That is a useful check against over-optimism at the company level too.

The bottom line is that AI can improve the Novartis equity story, but only if it reinforces what investors already watch most closely: faster development, better launches, lower cost, and stronger margins.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	On May 7, 2026, MarketScreener listed 22 analysts on the Novartis ADR with a Hold consensus, average target USD 155.06, low target USD 121.07, and high target USD 178.42.	Analysts see only modest upside on the ADR, which implies the market already gives meaningful credit to quality and capital returns.	That makes execution on priority brands and generic erosion the main swing factors.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

What AI means for long-term investors

AI should be treated as a multiplier on the existing Novartis model. The stock already has quality characteristics, so AI upside is most likely to appear as better compounding, not as a sudden speculative premium.

The review dates are the annual report, future technology-platform updates, and whether management starts tying AI more explicitly to development speed, cost outcomes, or margin progression.

AI scenario map for Novartis

Scenario	Probability	Target range	Trigger	When to review
AI upside	30%	CHF 220 to CHF 280 by 2035	AI materially improves pipeline productivity, operating cost, and commercial execution.	Review annually and after platform milestones.
AI base case	50%	CHF 160 to CHF 210 by 2035	AI helps compounding, but the stock still trades primarily on pharma fundamentals.	Review after each annual result.
AI disappointment	20%	CHF 110 to CHF 150 by 2035	AI use cases stay broad but only incrementally valuable in financial terms.	Review if the company stops linking AI to measurable outcomes.

References